MEDWIN PUBLISHERS
Committed to Create Value for Researchers

Pharmaceutical Drug Regulatory Affairs Journal

ISSN: 2642-6315

Quality by Design in Modern Pharmaceutical Development: From QbD to Quality by Digital Design

Gaikwad S* and Sonali B

Department of Pharmaceutical Chemistry, Jaihind College of Pharmacy, India

***Corresponding author:** Suresh Gaikwad, Department of Pharmaceutical Chemistry, Jaihind College of Pharmacy, India

Mini Review

Volume 8 Issue 1

Received Date: September 08, 2025

Published Date: September 24, 2025

Abstract

Quality by Design (QbD) has become an important scientific framework in pharmaceutical development because it emphasizes systematic understanding of products and manufacturing processes rather than relying exclusively on end-product testing. Advances in artificial intelligence, machine learning, digital twins, Process Analytical Technology, and real-time monitoring are now creating opportunities to extend traditional QbD toward digitally enabled quality systems. This mini review discusses the fundamental principles of QbD, the role of critical quality attributes and critical process parameters, the contribution of PAT and advanced analytics, and the emerging concept of Quality by Digital Design. The integration of digital technologies may improve process understanding and pharmaceutical quality, but successful implementation will require reliable data, validated models, regulatory alignment, and appropriately trained personnel.

Keywords: Quality by Design; QbD; Quality by Digital Design; Pharmaceutical Development; PAT; Critical Quality Attributes; Digital Manufacturing

Introduction

Pharmaceutical quality has traditionally depended heavily on testing finished products against predefined specifications. Although finished-product testing remains essential, it provides limited information about why a product achieved or failed to achieve a particular quality characteristic. Quality by Design offers a different approach. Instead of attempting to test quality into a product after manufacturing, QbD seeks to build quality into the development and manufacturing process through scientific understanding and systematic risk management.

Fundamental Principles of QbD

QbD begins with clearly defining the intended quality profile of a pharmaceutical product. From this starting point, developers identify critical quality attributes (CQAs) that may influence product performance, safety, or efficacy. The next step involves identifying critical material attributes and critical process parameters that can influence those CQAs. Risk assessment and experimental design can then be used to understand relationships among these variables. This approach creates a scientific basis for establishing an appropriate design space.

Role of Design of Experiments

Design of Experiments (DoE) is an important component of QbD. Instead of changing one variable at a time, DoE allows researchers to investigate multiple factors systematically. This can help identify interactions between formulation and process variables. For example, changes in material characteristics may interact with processing conditions and produce effects that would not be identified through isolated experiments.

DoE therefore contributes to a more comprehensive understanding of pharmaceutical processes.

Process Analytical Technology

PAT extends QbD into manufacturing. Instead of relying primarily on testing samples after production, PAT allows process information to be obtained during manufacturing. Spectroscopic methods, imaging technologies, sensors, and multivariate analysis can provide information about process behavior. When PAT data are integrated with appropriate control strategies, manufacturers can respond to process changes more rapidly.

From QbD to QbDD

Digital technologies are now creating a further evolution of the QbD concept. Quality by Digital Design integrates AI, machine learning, digital twins, advanced data analytics, PAT, and real-time release concepts into pharmaceutical development and manufacturing. Recent research describes QbDD as a framework capable of supporting predictive control, real-time optimization, adaptive quality assurance, and sustainability [1].

This represents an important shift. Traditional QbD asks how formulation and process variables influence quality. QbDD can potentially answer this question continuously using real-time data and computational models.

Artificial Intelligence and Pharmaceutical Quality

AI can analyze complex relationships between process variables and quality attributes. Machine-learning models may support anomaly detection, predictive stability assessment, process monitoring, and inferential measurements. Recent research has specifically examined AI-assisted pharmaceutical analysis for quality monitoring and continuous manufacturing applications [2]. However, AI models should not be accepted simply because they produce accurate predictions in development datasets. Their performance must be evaluated under conditions representative of real manufacturing.

Digital Twins

Digital twins represent another emerging technology. A digital twin is a computational representation of a physical manufacturing process that can be updated using real-world data. In principle, a pharmaceutical digital twin could help simulate process behavior, evaluate potential changes, predict deviations, and support process optimization. The practical implementation of such systems remains challenging because pharmaceutical processes generate complex and heterogeneous data.

Challenges

Several barriers must be addressed before digital QbD becomes widespread. First, data must be reliable and appropriately structured. Second, AI models must be validated and monitored over time. Third, cybersecurity and data integrity must be maintained. Fourth, regulatory expectations must accommodate increasingly dynamic and computationally assisted quality systems. Finally, pharmaceutical organizations need personnel capable of combining formulation science, process engineering, statistics, data science, and regulatory knowledge.

Future Perspective

The future of QbD is unlikely to involve abandoning its fundamental principles. Instead, digital technologies may strengthen them. QbDD could allow pharmaceutical manufacturers to move toward increasingly predictive and adaptive quality systems while maintaining the scientific foundations of conventional QbD [2].

Conclusion

Quality by Design has transformed pharmaceutical development by emphasizing scientific understanding and proactive quality management. The integration of AI, PAT, digital twins, and advanced analytics offers an opportunity to extend this philosophy into a digitally connected manufacturing environment. However, digitalization should remain a means rather than an objective. The ultimate purpose of QbDD should be the same as QbD: consistent pharmaceutical quality, reliable manufacturing, regulatory confidence, and protection of patients.

References

1. Abdulhussain R, Muhamad H, Fiza T, Dereiah S, Mawla N, et al. (2026) The integration of artificial intelligence through quality by digital design for sustainable pharmaceutical manufacturing. Int J Pharm 693: 126682.
2. Gaikwad AS, Pawar SB (2026) Artificial intelligence assisted pharmaceutical analysis for sustainable quality monitoring and continuous manufacturing applications. Discover Artificial Intelligence 6: 820.

Copyright© Gaikwad S and Sonali B.